Yue Han

Yue Han


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
WLWei Li
Wei Li
XXXiaoqiang Xu
Xiaoqiang Xu
HWHe Wen
He Wen
ZWZhifeng Wang
Zhifeng Wang
CDChao Ding
Chao Ding
XYXu Yao
Xu Yao

10 July 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
JLJinger Lin
Jinger Lin
XCXiangqi Chen
Xiangqi Chen
MLMin Luo
Min Luo
QZQianwei Zhuo
Qianwei Zhuo
HZHaosong Zhang
Haosong Zhang
YHYue Han
Yue Han
Background: Tildrakizumab, the IL-23 inhibitor, is used to treat plaque psoriasis and psoriatic arthritis. Many studies have reported adverse drug reactions (ADRs) associated with Tildrakizumab.Objective: The aim of this study was to describe ADRs associated with Tildrakizumab monotherapy by mining data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS).Methods: The signals of Tildrakizumab-associated ADRs were quantified using disproportionality analyses such as the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multiitem gamma Poisson shrinker (MGPS) algorithms.Results: A total of 10,530,937 reports of ADRs were collected from the FAERS database, of which 1,177 reports were identified with tildrakizumab as the “primary suspect (PS)”. Tildrakizumab-induced ADRs occurred against 27 system organ classes (SOCs). A total of 32 significant disproportionality Preferred Terms (PTs) conformed to the algorithms. Unexpected significant ADRs such as coronavirus infection, herpes simplex, diverticulitis, atrial fibrillation and aortic valve incompetence were also possible. The median time to onset of Tildrakizumab-associated ADRs was 194 days (interquartile range [IQR] 84–329 days), with the majority occurring, within the first 1 and 3 months after initiation of Tildrakizumab.Conclusion: This study identified a potential signal for new ADRs with Tildrakizumab, which might provide important support for clinical monitoring and risk prediction.

25 August 2020 in Chinese Medical Journal
Verified
Journal Article
Open access
XXXue-Min Xiao
Xue-Min Xiao
PZPeng-Jun Zhou
Peng-Jun Zhou
CZChang-Hua Zhu
Chang-Hua Zhu
LLLi-Hang Lin
Li-Hang Lin
JLJing-Jing Liu
Jing-Jing Liu
YHYue Han
Yue Han

27 November 2023 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
MLMin Luo
Min Luo
YZYaxuan Zheng
Yaxuan Zheng
QZQianwei Zhuo
Qianwei Zhuo
LLLihang Lin
Lihang Lin
YHYue Han
Yue Han

19 November 2024 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
JLJinger Lin
Jinger Lin
MLMin Luo
Min Luo
QZQianwei Zhuo
Qianwei Zhuo
NCNuo Chen
Nuo Chen
HZHaosong Zhang
Haosong Zhang
YHYue Han
Yue Han
Background: Lebrikizumab, an IL-13 immunomodulator, has shown recommendable effectiveness and safety in clinical studies for the treatment of moderate-to-severe atopic dermatitis (AD) in adolescents and adults.Objective: To evaluate the efficacy and safety of lebrikizumab in the treatment of moderate-to-severe AD through a meta-analysis.Methods: PubMed, Embase, Web of Science, Medline, and ClinicalTrials.gov databases were searched up to 8 August 2023. Randomized clinical trials of lebrikizumab treatment for moderate-to-severe AD were included by screening titles, abstracts, and papers.Results: Five studies involving 1,551 patients with AD were identified. Pooled analysis revealed significant improvements in the Eczema Area and Severity Index (EASI) score (SMD = −0.527; 95% CI = [−0.617, −0.436]), Investigator’s Global Assessment (IGA) score (RR = 2.122; 95% CI = [1.803, 2.496]), Body Surface Area (BSA) score (SMD = −0.608; 95% CI = [−1.099, −0.118]), SCORing Atopic Dermatitis (SCORAD) score (SMD = −0.441; 95% CI = [−0.633, −0.250]). Moreover, Pruritus Numeric Rating Scale (P-NRS) score, Patient-oriented Eczema Measure (POEM) scores, Sleep-loss score and Dermatology Life Quality Index (DLQI) scores showed similar results. Adverse events (AEs) (RR = 0.984; 95% CI = [0.907, 1.068]) for lebrikizumab showed no statistically significant difference compared to placebo, with similar results for serious adverse events (SAEs) (RR = 0.748; 95% CI = [0.410, 1.364]).Conclusion: This meta-analysis reveals that lebrikizumab has higher efficacy and safety in the treatment of moderate-to-severe AD, with the 250 mg Q2W dosage regimen appearing to be more advantageous.

12 April 2024 in Medicine
Verified
Journal Article
Open access
JLJinger Lin
Jinger Lin
MLMin Mm Luo
Min Mm Luo
QZQianwei Mm Zhuo
Qianwei Mm Zhuo
HZHaosong Zhang
Haosong Zhang
NCNuo Chen
Nuo Chen
YHYue Han
Yue Han
Basal cell carcinoma (BCC) represents the most prevalent cancer globally. The past decade has witnessed significant advancements in BCC treatment, primarily through bibliometric studies. Aiming to perform a comprehensive bibliometric analysis of BCC treatments to comprehend the research landscape and identify trends within this domain, a dataset comprising 100 scientific publications from the Web of Science Core Collection was analyzed. Country co-operation, journal co-citation, theme bursts, keyword co-occurrence, author co-operation, literature co-citation, and field-specific references were examined using VOSviewer and CiteSpace visualization tools. These articles, published between 2013 and 2020, originated predominantly from 30 countries/regions and 159 institutions, with the USA and Germany at the forefront, involving a total of 1118 authors. The keyword analysis revealed significant emphasis on the hedgehog pathway, Mohs micrographic surgery, and photodynamic therapy. The research shows developed nations are at the forefront in advancing BCC therapies, with significant focus on drugs targeting the hedgehog pathway. This treatment avenue has emerged as a crucial area, meriting considerable attention in BCC therapeutic strategies.